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Hand osteoarthritis (HOA) includes different subsets; a particular and uncommon form is erosive HOA (EHOA). Interleukin- (IL-)
1β plays a crucial role in the pathogenesis of osteoarthritis (OA); it is synthesized as an inactive precursor which requires the
intervention of a cytosolic multiprotein complex, named inflammasome, for its activation. The aim of this study was to
investigate the involvement of IL-1β and the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome in patients
with EHOA and nonerosive HOA (NEHOA) compared to healthy controls. In particular, we evaluated the gene expression of
IL-1β and NLRP3, the serum levels of IL-1β, IL-6, IL-17, and tumor necrosis factor- (TNF-) α, and the protein levels of IL-1β
and NLRP3. We also assessed the relationships between IL-1β and NLRP3 and clinical, laboratory, and radiological findings.
Fifty-four patients with HOA (25 EHOA and 29 NEHOA) and 20 healthy subjects were included in the study. Peripheral blood
mononuclear cell (PBMC) gene and protein expressions of IL-1β and NLRP3 were quantified by quantitative real-time PCR and
western blot. IL-1β, IL-6, IL-17, and TNF-α serum levels were determined by ELISA. IL-1β gene expression was significantly
reduced (p = 0 0208) in EHOA compared to healthy controls. NLRP3 protein levels were significantly increased in the NEHOA
group versus the control (p = 0 0063) and EHOA groups (p = 0 0038). IL-1β serum levels were not significantly different across
the groups; IL-6, IL-17, and TNF-α were not detectable in any sample. IL-1β concentrations were negatively correlated with the
Kellgren-Lawrence score in the whole population (r = −0 446; p = 0 0008) and in NEHOA (r = −0 608; p = 0 004), while IL-1β
gene expression was positively correlated with the number of joint swellings in the EHOA group (r = 0 512; p = 0 011). Taken
together, our results, showing poorly detectable IL-1β concentrations and minimal inflammasome activity in the PBMCs of
HOA patients, suggest a low grade of systemic inflammation in HOA. This evidence does not preclude a possible involvement
of these factors at the local level.
1. Introduction
Osteoarthritis of the hand (HOA) is a common form of oste-
oarthritis (OA), affecting a large percentage of the population
over 50 years [1]. HOA is generally considered a heteroge-
neous group of diseases including different subsets [2]. A
particular and uncommon subset of HOA is the so called
erosive osteoarthritis of the hand (EHOA) characterized by
an abrupt onset, inflammatory signs, and importantly, more
disability than nonerosive hand OA (NEHOA) [3]. EHOA
mainly affects the distal and proximal interphalangeal (IP)
joints with prominent destructive damage, consisting of sub-
chondral erosions and bone ankylosis [4, 5]. The diagnosis of
EHOA is commonly based on characteristic radiographical
changes including typical central erosions, collapse of the
subchondral bone, and the “gull-wing” and/or “saw-tooth”
deformity [4]. Laboratory findings, including rheumatoid
factor, anticyclic citrullinated peptide antibodies are usually
negative, while contrasting data have been reported about
erythrocyte sedimentation rate (ESR) and high sensitivity C
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reactive protein (hsCRP) levels [6–8]. Recent data from var-
ious pilot studies showed an increase of biomarkers of joint
inflammation such as myeloperoxidase [9–11].
There has been much debate in recent years regarding the
role of systemic inflammation in erosive and nonerosive
HOA [12, 13]. Different inflammatory cytokines, such as
interleukin- (IL-) 1β, IL-6, IL-17, and tumor necrosis factor
alpha (TNF-α), released from various cell types can promote
HOA cartilage degradation, synovial inflammation, and dis-
ease progression [14–17].
IL-1β plays a crucial role in the local pathogenesis of OA
leading to the release of cartilage-degrading enzymes, such as
metalloproteinases (MMPs) and aggrecanases (ADAMTS-4
and 5), from chondrocytes and inhibiting the production of
the extracellular matrix [18, 19]. IL-1β is synthesized as an
inactive precursor (pro-IL-1β) which requires cleavage of
its amino-terminal region by caspase 1 to produce the active
form. The activation from pro-caspase 1 to caspase 1 requires
the intervention of large cytosolic multiprotein complexes,
named inflammasomes [20]. NOD-like receptor pyrin
domain containing 3 (NLRP3) is the most studied subtype
of inflammasome. Inflammasome proteins are mainly
expressed in innate immune cells, as monocytes and macro-
phages, as well as in neutrophils and mesenchymal cells,
including osteoblasts and chondrocytes [21]. NLRP3 is acti-
vated by danger-associated molecular patterns (DAMPs)
and pathogen-associated molecular patterns (PAMPs), such
as ATP and crystalline agonists including calcium pyrophos-
phate dihydrate (CPPD) andmonosodium urate (MSU) [22].
Other pathways of activation of pro-IL-1β are mediated by
some extracellular proteases (trypsin, chymotripsin, cathep-
sin G, and elastase) or by MMPs, particularly MMP-9 [23].
In the last decade, several studies have highlighted the
central role of the NLRP3 inflammasome in the pathogenesis
of inflammatory and immune disorders [24]. Conversely,
there are few contrasting reports about the involvement of
NLRP3 inflammasome in the pathophysiology of OA [25].
The aim of this study was to investigate the possible
involvement of IL-1β and the NLRP3 inflammasome in
patients with EHOA and NEHOA in comparison to healthy
controls. In particular, we evaluated the gene expression and
the protein levels of IL-1β and NLRP3 by quantitative
real-time PCR and western blot analysis in the peripheral
blood mononuclear cells (PBMCs); in addition, the serum
levels of IL-1β, IL-6, IL-17, and TNF-α by the ELISA assay
were also assessed. Furthermore, we investigated the rela-
tionships between IL-1β and NLRP3 and the clinical, labora-
tory, and radiological parameters studied in EHOA and
NEHOA patients.
2. Patients and Methods
2.1. Study Population. Fifty-four Caucasian outpatients who
fulfilled the American College of Rheumatology criteria for
hand osteoarthritis [26] were recruited in the Rheumatol-
ogy Unit of Siena Hospital from December 2014 to March
2016. All patients underwent radiographic examination of
the hands.
Patients were divided into EHOA and NEHOA groups.
EHOA was defined by the presence of the classical central
erosion in at least two IP joints [4]. We identified 25 EHOA
patients and 29 NEHOA. A control group was represented
by 20 healthy subjects without hand joint pain and/or tender-
ness and finger nodes. These subjects did not show clinical
signs of OA in any articular joints and were not affected by
other autoimmune or inflammatory disorders.
The main exclusion criteria included the presence of
inflammatory rheumatic and bowel diseases and personal
and/or familial history of psoriasis. Furthermore, patients
treated in the last year with immunosuppressants or symp-
tomatic slow-acting drugs for osteoarthritis (SySADOA),
such as chondroitin sulphate, glucosamine sulphate, dia-
cerein, avocado/soybean unsaponifiables, and intra-articular
hyaluronic acid or nutraceuticals [27], were excluded.
All participants gave written informed consent before
inclusion. The study was approved by the Local Ethical
Committee (decision no. 30.11.07).
2.2. Clinical and Radiographic Assessment. Demographic and
clinical data including age, gender, height, weight, BMI, dis-
ease duration, concomitant hip and knee OA involvement
[28], smoking, and medical history of type II diabetes melli-
tus, hypertension, cardiovascular (CV) diseases, or autoim-
mune thyroiditis were collected at the time of enrollment.
All patients underwent an anteroposterior X-ray projection
of both hands; the radiological assessment was carried out
by consensus opinion (joint wise at the same time) by two
experienced readers, according to the Kellgren-Lawrence
score [29].
Clinical evaluation also included swollen joint count,
ESR, serum CRP concentrations, the patient’s assessment of
spontaneous hand pain on a 0-100mm visual analogue scale
(VAS), and the functional index for hand osteoarthritis
(FIHOA) validated in Italian language [30, 31].
2.3. Serum Collection and Isolation of PBMCs.Overnight fast-
ing blood samples (6ml) were obtained from an antecubital
vein with the subject in the supine position. The blood was
immediately centrifuged, and the serum was stored at -80°C
until following analysis. EDTA-treated blood was separated
in its fractions by Ficoll (Ficoll-Paque GE Healthcare, UK)
density gradient centrifugation to collect the plasma and
PBMCs. The total cell lysates were obtained with M-PER™
Mammalian Protein. Extraction Reagent (Thermo Fisher Sci-
entific, Rockford, IL, USA) containing a protease inhibitor
cocktail (Sigma-Aldrich S.r.l., Milan, Italy), while the total
RNA was extracted from PBMCs using the TRIzol reagent
according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, USA).
2.4. ELISA Assay of IL-1β, IL-6, IL-17A, and TNF-α. IL-1β
levels were quantified using the Cymax™ Human ultrasensi-
tive IL-1β ELISA assay (L.O.D. 1.90 pg/ml; Ab Frontier,
Korea).
IL-6 and TNF-α serum levels were quantified using the
Human IL-6 PicoKine ELISA kit (L O D <0 3 pg/ml) and
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Human TNF-α PicoKine ELISA kit (L O D <1 pg/ml),
respectively (Vinci-Biochem srl., Italy).
IL-17 serum levels were assessed by Human IL-17A
Platinum Kit ELISA (L.O.D. 1.6 pg/ml; Invitrogen, Thermo
Fisher Scientific, Italy).
Reagents and assay procedures were prepared according
to the manufacturer’s guidelines. The products of the enzy-
matic reactions were immediately read by a Microplate Spec-
trophotometer (Tecan Group Ltd., Switzerland) and by a
Microplate Reader (BioTek Instruments Inc., USA). A stan-
dard curve was created from plate data, and the unknown
values were extrapolated in Microsoft Excel.
2.5. RNA Extraction and Real-Time PCR. Real-time PCR was
used to measure gene expression of NLRP3 and IL-1β relative
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
RNA was extracted from cell pellets which were already
stored in TRIzol Reagent (Thermo Fisher, U.S.A.). The con-
centration of RNA was measured using the NanoDrop 2000
(Thermo Fisher, U.S.A.). cDNA was then reverse transcribed
from 80ng of RNA using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, U.K.) on the Prime
Thermal Cycler (Techne, U.K.).
Real-time PCR was performed using the LightCycler 480
II and the LightCycler 480 ProbeMaster Reagents and probes
(Roche, Switzerland). PCR grade water, a minus RT control,
a probe control (probe, probe master mix control, and
water), and a cDNA control (cDNA template, PCR grade
water, and probe master mix) were run on each plate. Gene
expression was normalized using GAPDH as a reference
gene, and relative expression values were determined using
the delta delta Ct calculation method, then plotted as ratios
of healthy control values.
2.6. Western Blot Analysis.Western blot analysis was used to
quantify the protein levels of IL-1β and NLRP3 relative to
β-actin.
Protein concentration of PBMC samples was determined
using Pierce BCA Protein Assay Kit (Thermo Scientific,
USA) to facilitate equal lane loading on western blot. IL-1β
and NLRP3 proteins were quantified using NuPAGE Electro-
phoresis System. Protein (17μg) from each sample was
loaded per lane and electrophoresed in 1xNuPAGE (MOPS)
SDS Running Buffer on NuPAGE 4-12% BisTris Gels. 500μl
of NuPAGE antioxidant per gel was used in the inner cham-
ber. Following electrophoresis, proteins were transferred
onto a PVDF membrane in 1x transfer buffer (20xNuPAGE
Transfer Buffer, 20% methanol, dH20, NuPAGE antioxi-
dant). Membranes were blocked in 5% Marvel and PBST
for one hour. Running buffer, gels, antioxidant, membranes,
and transfer buffer were purchased from Life Technologies,
USA. Membranes were also exposed to anti-IL-1β goat IgG
(R&D, USA) diluted 1 : 200 in PBS overnight at 4°C, washed
in PBST, and incubated with rabbit anti-goat IgG-HRP
(Santa Cruz Biotechnology) diluted 1 : 2000 in PBS for one
hour at room temperature (a human recombinant IL-1β
positive control protein sample was used to verify the
method). Membranes were developed using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific,
USA) and imaged using UVP ChemiDoc-It2 Imager and
VisionWorks Analysis Software version 7.1. β-Actin was
used as a loading control.
Background subtraction was done, and band densitome-
try was used to normalize IL-1β and NLRP3 to β-actin for
each sample.
2.7. Statistical Analysis. Continuous parameters are
expressed as mean and standard deviation (SD); categorical
variables are expressed as frequency and percentages.
Comparison for continuous normally distributed clinical,
demographic, and biochemical variables between two groups
was performed by t-test and among three groups by the
analysis of variance (ANOVA) test; the nonparametric
Mann-Whitney test was used for nonnormal variables. Fre-
quency comparisons between two groups and three groups
were analyzed using the χ2 (chi square) test and contingency
table method, respectively.
Correlations were obtained and expressed as Pearson
correlation coefficient (r), α (two-sided) was set at 0.05,
and study power = 95%. Statistical analysis was performed
with Prism 6.01 (GraphPad Software Inc., California,
USA). For all tests, a p value <0.05 was considered as statis-
tically significant.
3. Results
3.1. Patients Characteristics. Demographic and clinical cha-
racteristics of the different study groups are summarized in
Table 1. Our study population was mainly represented by
female patients (78.3%); Kellgren and Lawrence radiological
grades were equally distributed between EHOA and NEHOA
patients. The three groups were also comparable for sex dis-
tribution, BMI, frequency of diabetes, CV diseases, autoim-
mune thyroiditis, concomitant knee/hip OA, and number
of hand joint swellings. However, subject age, frequency of
smoking, and hypertension significantly differed among the
three groups (p = 0 001, p = 0 0110, and p = 0 0012, respec-
tively). Particularly, the control group was represented by
subjects younger than those affected by EHOA and NEHOA
(p < 0 001) with a lower percentage of concomitant hyper-
tension (p < 0 001) and a greater frequency of smokers
(p = 0 007 and p = 0 035, respectively).
Concerning laboratory measurements, no differences
were found in ESR values among the three groups. Con-
versely, for CRP, we observed a significant difference among
the three groups (p = 0 0125) and between the EHOA and
NEHOA groups (p = 0 003).
The disease duration, the assessment on 0-100mm VAS
pain, and the algofunctional index, FIHOA, were significantly
greater in EHOA versus NEHOA (p = 0 0175, p = 0 0039, and
p = 0 0020, respectively).
3.2. Circulating Levels, Gene Expression, and Protein Levels of
IL-1β. IL-1βmeasured by the ELISA assay showed no signif-
icant differences among the three studied groups (Figure 1(a)).
Figure 1(b) indicates the analysis of IL-1β by quantitative
real-time PCR. IL-1β gene expression was significantly lower
(p = 0 0208) in EHOA patients in comparison to the control
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group; no significant differences were observed in compari-
son to the NEHOA group. Patients with NEHOA showed
slightly lower IL-1β expression levels than controls, although
in a not significant manner. Three samples were not analyzed
as the extracted RNA quality was poor, and another 3 samples
were not included in the analysis as Ct values were over
40. IL-1β protein expression was not detected by western
blotting (data not shown).
Table 1: Demographic and clinical characteristics of the study populations.
EHOA (N = 25) NEHOA (N = 29) Control (N = 20) p value
Age (years) 70 16 ± 8 23 65 44 ± 10 26 52 15 ± 7 49 0.001a°
Sex, no. of male/female 3/22 7/22 6/14 0.2606b
BMI (kg/m2) 25 89 ± 3 62 24 15 ± 3 04 24 46 ± 4 76 0.0603a
Radiographic score (K-L grade) no. (%)
I 0 (0) 2 (7) NA 0.1876c
II 11 (44) 18 (62) NA 0.1910c
III 14 (56) 9 (31) NA 0.0663c
Smoker no. (%) 1 (4) 3 (10) 7 (35) 0.0110b#
Diabetes no. (%) 4 (16) 6 (21) 1 (5) 0.310b
CV disease no. (%) 2 (8) 3 (10) 0 (0) 0.3496b
Hypertension no. (%) 12 (48) 12 (41) 0 (0) 0.0012b##
Autoimmune thyroiditis no. (%) 4 (16) 7 (28) 0 (0) 0.0643b
HOA+knee/hip OA no. (%) 6 (24) 4 (13) NA 0.5675c
Disease duration (months) 152 32 ± 78 39 96 20 ± 88 13 NA 0.0175d
No. of hand joint swellings 3 52 ± 3 25 1 75 ± 4 27 NA 0.0966d
ESR (mm/h) 21 8 ± 14 61 17 93 ± 10 55 18 05 ± 12 01 0.2651a
CRP (mg/dl) 0 39 ± 0 32 0 16 ± 0 20 0 22 ± 0 33 0.0125a°°
VAS pain (0-100mm) 38 8 ± 26 20 19 77 ± 19 98 NA 0.0039e
FIHOA (0-30) 10 52 ± 5 78 5 65 ± 5 23 NA 0.0020e
EHOA: erosive osteoarthritis of the hand; NEHOA: nonerosive osteoarthritis of the hand; NA: not applicable; BMI: body mass index; K-L grade:
Kellgren-Lawrence grade; CV: cardiovascular; HOA: osteoarthritis of the hand; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; VAS: visual
analogue scale; FIHOA: functional index for hand osteoarthritis. p values <0.05 were considered significant. aANOVA test for multiple comparison; b3 × 2
contingency table method; cchi square test; dMann-Whitney test; eunpaired t-test. °EHOA group vs. control group: p < 0 001; EHOA group vs. NEHOA
group: p = 0 071; NEHOA group vs. control group: p < 0 001 (p value was estimated by t-test). #EHOA group vs. control group: p = 0 007; EHOA group
vs. NEHOA group: p = 0 374; NEHOA group vs. control group: p = 0 035 (p value was estimated by the chi square test). ##EHOA group vs. control group:
p = 0 0003; EHOA group vs. NEHOA group: p = 0 625; NEHOA group vs. control group: p = 0 0009 (p value was estimated by the chi square test).
°°EHOA group vs. control group: p = 0 135; EHOA group vs. NEHOA group: p = 0 003; NEHOA group vs. control group: p = 0 378 (p value was
estimated by t-test).
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Figure 1: Evaluation of IL-1β at the serum level (a) by the ELISA assay and at the gene expression level (b) by real-time PCR, in a control
group, patients with erosive hand OA (EHOA), and patients with nonerosive hand OA (NEHOA). The gene expression was normalized to
controls. Data are expressed as mean ± standard deviation. ∗p < 0 05 versus control group.
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3.3. Gene Expression and Protein Levels of NLRP3. In the
PBMCs of the three groups, there was no statistical difference
of NLRP3 gene expression (Figure 2(a)). Three samples were
not analyzed as the extracted RNA quality was poor.
Figures 2(b) and 2(c) showed the western blot analysis of
NLRP3. Some samples were excluded as protein concentra-
tions measured by the BCA assay were not sufficient. The
densitometric quantification of the bands showed a signifi-
cant increase (p = 0 0063) of NLRP3 protein levels in the
NEHOA group in comparison to controls. In addition,
NLRP3 protein levels were significantly higher in the
NEHOA group (p = 0 0038) than in the EHOA group. No
significant differences were observed between EHOA
patients and controls.
3.4. Serum Levels of IL-6, IL-17A, and TNF-α. The ELISA
assay carried out on IL-6, IL-17A, and TNF-α serum levels
resulted in nondetectable levels for all samples analyzed (data
not shown).
3.5. Correlation Analysis between IL-1β and NLRP3 and the
Other Parameters Studied. Figure 3 shows the existing corre-
lations between serum levels and gene expression of IL-1β
and the Kellgren-Lawrence score and the number of hand
joint swellings, respectively. In particular, IL-1β concentra-
tions were negatively correlated in a significant manner with
the radiological grade, measured by the Kellgren-Lawrence
score in the whole population (r = −0 446; p = 0 0008) and
in the NEHOA group (r = −0 608; p = 0 004) (Figures 3(a)
and 3(b)).
IL-1β gene expression significantly and positively corre-
lated with the number of hand joint swellings only in the
EHOA group (r = 0 512; p = 0 011) (Figure 3(c)). No other
correlations were observed either between IL-1β and the
other evaluated parameters or between gene expression
and protein levels of NLRP3 and the clinical, laboratory,
and radiological findings in the whole population and in
each subgroup.
4. Discussion
To the best of our knowledge, this is the first study to inves-
tigate more deeply the involvement of IL-1β and NLRP3 in
PBMCs of patients with two clinically important subsets of
HOA, erosive and nonerosive forms.
Despite the fact that many in vitro studies have well doc-
umented the important contribution of IL-1β to the OA
pathogenesis, the role of this cytokine in the clinical setting
has not been fully elucidated. On one hand, IL-1β has been
shown to affect cartilage homeostasis and to drive the synthe-
sis of proteolytic enzymes, such as MMPs, ADAMTs, and the
production of other cytokines such as IL-8, IL-6, and IL-17
[32, 33]. Conversely, data from different OA animal models
reported discordant results; mice deficient in IL-1 developed
more severe cartilage lesions than wild-type (WT) mice
[34], and intraperitoneal injections of IL-1 antagonists did
not improve the OA injuries in a meniscectomy-induced
murine model of OA [35]. Furthermore, clinical evidence
demonstrated very low levels of IL-1β in the synovial
membrane and fluid of patients affected by early- and
end-stage OA [36].
A potential role for IL-1β in the pathogenesis of HOA,
in particular in the severe subset of EHOA, was suggested
by some authors [37, 38]. Stern et al. [37] reported the asso-
ciation between a single nucleotide polymorphism (SNP)
identified on the gene-encoding IL-1β and the development
of EHOA.
Surprisingly, in our study, IL-1β gene expression was
marginally lower in erosive patients than nonerosive
patients although this wasn’t statistically significant. There
was, however, a statistical difference between the control
group and the erosive group, with higher IL-1β expression
seen in the controls. Protein levels of IL-1β resulted not
detectable in all samples, and its serum levels were around
the limits of detection without any difference among the
three groups.
Currently, it is difficult to explain the discrepancy
between the results obtained at IL-1β gene expression and
serum levels. We can postulate that this difference may be
due to the increase in the percentage of IL-1β bound to
its receptors. Intriguingly, a higher density of IL-1 receptors
has been reported in osteoarthritic chondrocytes compared
to healthy controls [39]; therefore, it would be interesting
to compare receptor density between erosive and nonero-
sive patients to verify our hypothesis. Furthermore, it was
demonstrated that the release of IL-1 occurred in the early
phases of OA, and this could represent another explanation
for the low IL-1β serum levels described in this paper,
considering that mean disease duration of our study popu-
lation was higher than 8 years [38]. Alternatively, we can
hypothesize a compensatory mechanism in place to
dampen the inflammatory response in the EHOA and
NEHOA patients.
Considering together, the results derived by IL-1β serum
levels and gene and protein expressions, an independent
mechanism from IL-1 pathways in cartilage degradation
and inflammation could be also supposed.
Recent evidence corroborates our results showing that
in meniscectomized knock out mice for IL-1β and inflam-
mosome complex, the severity of cartilage lesions was sim-
ilar or worse than in meniscectomized WT mice [34, 40].
Besides the pivotal role of IL-1β in OA, it has also been
targeted with the IL-1 receptor antagonist (IL-1Ra) in ran-
domized clinical trial (RCT) patients with knee OA. Both
intra-articular anakinra, a recombinant form of IL-1Ra,
and subcutaneous use of AMG108, a monoclonal antibody
against IL-1R1, failed to demonstrate significant clinical
efficacy [41, 42]. Concerning HOA, the data are limited
to two different reports of 3 cases of severe EHOA suc-
cessfully treated with subcutaneous injections of anakinra
[43, 44].
In the current study, we analyzed the possible involve-
ment of NLRP3 in erosive and nonerosive HOA.
NLRP3 is an intracellular complex that mediates the
cellular response to exogenous and endogenous pathogens,
regulating the release of proinflammatory cytokines, mainly
IL-1β. Thus, the inflammasome plays a paramount role not
only in the process of host protection against infective agents,
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but also in the rheumatic inflammatory diseases [45]. How-
ever, the role of NLRP3 in OA appears highly controversial.
Some studies have reported an overexpression of NLRP3
protein in synovial tissue from OA joints compared to con-
trols and a positive correlation with nicotinamide adenine
dinucleotide phosphate oxidase- (Nox-) 2, a prooxidant
enzyme involved in oxidative stress [46, 47]. Other studies
suggested that OA cartilage degradation occurs indepen-
dently of NLRP3 inflammasome activity [40, 48]. In
particular, Bougault et al. [48] found that the IL-1β release
from cartilage explants of 18 knee OA patients who under-
went total joint replacement was poorly detectable and
lower than synovial samples. The authors also reported
the protein and gene expressions of NLRP3, ASC, and
caspase-1 in human OA chondrocytes, although they
seemed to acquire a prodegradative phenotype without
any contribution by NLRP3 and IL-1β. Indeed, the protein
and gene expressions of MMPs in knock out (NLRP3-/-)
and WT mice did not differ, and the caspase-1 inhibition
leads to nonsignificant modifications. Similar results were
also obtained after biochemical load stimulation of mouse
cartilage explants.
Our results did not show any significant difference in
NLRP3 gene expression between the three subgroups. Con-
versely, NLRP3 protein expression was significantly higher
in the NEHOA group compared to EHOA and controls.
The different pattern showed by gene expression and protein
levels of NLRP3 could be due to posttranslational modifica-
tions or mRNA instability which could affect protein expres-
sion [49, 50]. Using reverse transcription-PCR, NLRP3, ASC,
caspase-1, and pro-IL-1β, messenger RNA was detected in
OA synovial tissue in either all cases or in the majority of
cases of a previous study [51]. Protein expression of NLRP3
was confirmed by western blot, which is in line with the cur-
rent results showing NLRP3 expression in PBMC samples of
those with OA [51].
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Figure 2: Evaluation of NLRP3 gene expression (a) by real-time PCR and of NLRP3 protein levels (b and c) by western blot analysis in a
control group, patients with erosive hand OA (EHOA), and patients with nonerosive hand OA (NEHOA). The gene expression was
normalized to controls. Data are expressed as mean ± standard deviation. ∗∗p < 0 01 versus control group; °°p < 0 01 EHOA group versus
NEHOA group.
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In our study, we showed low NLRP3 protein expression
in EHOA patients compared to NEHOA and controls, even
if EHOA is characterized by clinical inflammatory features
and radiographic erosions, as main hallmarks. Presently, it
is very difficult to explain these results.
One possible hypothesis is the higher, although not statis-
tically significant, frequency of certain comorbidities, such as
type II diabetes, CV diseases, and autoimmune thyroiditis in
the nonerosive group compared to the erosive group. There is
evidence suggesting these conditions enhance the NLRP3
inflammasome expression [52–54]. We have also to take into
consideration that the control group included a higher per-
centage of smokers compared with both EHOA and NEHOA
patients. It was demonstrated that nicotine exposure could
induce NLRP3 inflammasome activation in endothelial cells,
mainly as a consequence of generation of reactive oxygen
species (ROS) and an increased IL-1β gene expression in
lung tissue extracts [55, 56]; moreover, an increase of IL-1β
concentrations was observed in smokers’ sera [57]. On the
other side, recent studies showed that cigarette smoke extract
decreased NLRP3 protein levels, through an increase of
ubiquitin-mediated proteasomal processing, and subse-
quently reduced the release of IL-1β in human THP1
monocytes [58]. Thus, at the moment, it is difficult to clarify
the exact effect of smoking on NLRP3 and IL-1β levels. It is
also important to highlight that our study analyzed the pro-
tein and gene expressions of IL-1β and NLRP3 in PBMCs
and not in cartilage cells. This method can have some limi-
tations in a disease characterized by a prominent local
inflammation, such as EHOA, because PBMCs reflect the
inflammatory state at a systemic level [12] Thus, it is very
difficult to obtain cartilage and synovial samples from IF
joints, and although monocytes, macrophages, and dendritic
cells are the main NLRP3-expressing cells, human neutro-
phils have also shown to have functional NLRP3 inflamma-
some [59]. Furthermore, PBMCs have been considered as a
common source of genomic material for microarray studies,
mainly due to the facility and relative noninvasiveness of
acquisition [60].
To understand if pathways other than those mediated by
NLRP3 inflammasome may be involved in the pathogenesis
of the two considered subsets of HOA, we measured the
serum levels of other known proinflammatory cytokines,
including IL-6, IL-17, and TNF-α. These cytokines were not
present at detectable levels (stating the lowest level of detec-
tion of the assays).
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Figure 3: Graphical representation of the found correlations between IL-1β serum levels and the Kellgren-Lawrence (K-L) score in the whole
population (a; r = −0 446, p = 0 0008) and in the NEHOA group (b; r = −0 608, p = 0 004) and IL-1β mRNA levels and the number of joint
swellings in the EHOA group (c; r = 0 512, p = 0 011).
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Our IL-6 results concur with previous studies, in patients
with HOA where circulating IL-6 levels were not statistically
different among NEHOA, EHOA, and healthy subjects [61,
62]. Conversely, others have demonstrated high synovial
and serum levels of IL-6 in subjects with knee OA in compar-
ison to the healthy controls [14, 63]. This inconsistency could
be explained by the evidence that the infrapatellar fat pad is a
source of cytokines, as IL-6, while the small joints of the hand
are characterized by a minor amount of adipose tissue [64].
A recent hypothesis defines IL-17 as a peculiar inflamma-
tory OA phenotype; in this regard, we analyzed the serum
levels of this cytokine in our HOA study groups [65, 66].
Unexpectedly, we detected very low concentrations of IL-17
in our HOA population, without any difference among the
examined groups. Others have described increased IL-17
serum levels in patients with knee OA compared to healthy
controls; however, no data have been previously published
in HOA [67–69].
Concerning serum levels of TNF-α, we observed no dif-
ference among the three analyzed groups. To the best of
our knowledge, there are no previous papers exploring the
circulating TNF-α levels in patients with EHOA, and data
derived from knee OA are controversial [63, 70]. After all,
the clinical studies aimed at assessing the efficacy of TNF-α
inhibitors (TNF-αi) in subjects with HOA are too heteroge-
neous to draw any clear conclusions. Indeed, three RCTs
enrolling HOA patients treated with adalimumab failed to
show the superiority of the TNF-αi over placebo [71–73].
On the other hand, a recent RCT reported encouraging
results on etanercept therapy in an EHOA population [74].
Also, previous open-label trials provided controversial out-
comes; Magnano et al. [75] observed no significant improve-
ments, after treatment with adalimumab in 12 patients with
EHOA, while a single-blind study on 10 EHOA patients sug-
gested a clinical benefit of intra-articular therapy with inflix-
imab [76].
We observed a negative correlation between IL-1β serum
levels and the radiographic Kellgren-Lawrence score in the
whole population and in the NEHOA group, but surpris-
ingly, it was not confirmed in EHOA patients. The lack of a
correlation in the EHOA group may be due to the missing
data regarding other radiological grades, as the Verbruggen
and Kallman scores, considered superior in measuring the
erosive lesions to the Kellgren-Lawrence [38]. This hypothe-
sis can be supported by the results reported by Bondeson
et al. [32]; in fact, the authors demonstrated a negative signif-
icant correlation between IL-1 serum levels and Verbruggen
and Kallman scores in EHOA patients but not with
Kellgren-Lawrence.
Furthermore, we detected a positive and significant
correlation between IL-1β gene expression and the num-
ber of hand joint swellings in the EHOA group. This
result may reflect the disease activity, as demonstrated by
the significantly higher CRP levels in our erosive patients
than NEHOA.
However, we are aware that our study presents several
limitations. Firstly, the number of patients is small, and the
three groups were not homogeneous for all the demographi-
cal and clinical measures; in particular, the controls were
younger than both the other study groups and maybe for this
reason presented a minor frequency of hypertension. They
were also smokers in a greater percentage than HOA
patients, and this could affect our IL-1β and NLRP3 results.
Secondly, the longer disease duration in EHOA patients
compared to the NEHOA group could have influenced the
gene and protein expressions of NLRP3 and IL-1β. Further-
more, the use of the radiographic scores of Verbruggen and
Kallman should allow to obtain a more appropriate assess-
ment of erosive lesions in EHOA.
Finally, our results may have been limited by the missing
analysis of inflammasome subtypes other than NLRP3 and
its multiple polymorphisms and measure of IL-18 another
major cytokine released via the NLRP3 pathway.
All these limitations, particularly the lack of homogeneity
among the three groups, induce us to consider our results as
preliminary and to advocate further studies in this field.
5. Conclusions
This study showed low serum, protein, and gene expression
levels of IL-1β in EHOA and NEHOA patients; we have
also observed low NLRP3 protein expression in EHOA
patients compared to NEHOA and controls, suggesting
the hypothesis of a nonpivotal role for NLRP3 in the path-
ogenesis of EHOA.
Furthermore, IL-6, IL-17, and TNF-α serum levels
resulted not detectable in all samples analyzed.
Finally, we found a negative correlation between
IL-1β serum and the radiological grade, measured by the
Kellgren-Lawrence score in the whole population and in the
NEHOA group and a positive correlation between IL-1β
gene expression and the number of hand joint swellings in
the EHOA group.
Taken together, our results, showing poorly detectable
concentrations of IL-1β and minimal inflammasome activity
in the PBMCs of patients with HOA, suggest a low grade of
systemic inflammation in HOA. This evidence does not pre-
clude a possible involvement of these factors at the local level.
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